Literature DB >> 15767363

Chromosomal instability in peripheral blood lymphocytes and risk of prostate cancer.

Randa El-Zein1, Yun Gu, Monica S Sierra, Margaret R Spitz, Sara S Strom.   

Abstract

Prostate cancer is an extremely complex disease, and it is likely that chromosomal instability is involved in the genetic mechanism of tumorigenesis. Several chromosomes have been labeled as "players" in the development of prostate cancer, among them chromosome 1 and X chromosome have been reported to harbor prostate cancer susceptibility loci. However, there is little information regarding the background levels of chromosome instability in these patients. In this pilot study, we examined spontaneous chromosome instability in short-term lymphocyte cultures from 126 study subjects, 61 prostate cancer patients, and 65 healthy controls. We evaluated chromosomal instability using a fluorescence in situ hybridization assay using two probes targeting specific regions on X chromosome and chromosome 1. Our results showed a significantly higher mean level of spontaneous breaks involving the X chromosome in patients compared with controls (mean +/- SE, 2.41 +/- 0.26 and 0.62 +/- 0.08, respectively; P < 0.001). Similarly, chromosome 1 spontaneous breaks were significantly higher among cases compared with controls (mean +/- SE, 1.95 +/- 0.24 and 1.09 +/- 0.16, respectively; P < 0.001). Using the median number of breaks in the controls as the cutoff value, we observed an odds ratio (95% confidence interval) of 15.53 (5.74 - 42.03; P < 0.001) for spontaneous X chromosome breaks and 3.71 (1.60 - 8.63; P < 0.001) for chromosome 1 breaks and risk of development of prostate cancer. In conclusion, our preliminary results show that spontaneous chromosome instability could be a risk factor for prostate cancer.

Entities:  

Mesh:

Year:  2005        PMID: 15767363     DOI: 10.1158/1055-9965.EPI-04-0236

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

1.  Single-nucleotide polymorphism array genotyping is equivalent to metaphase cytogenetics for diagnosis of Turner syndrome.

Authors:  Siddharth Prakash; Dongchuan Guo; Cheryl L Maslen; Michael Silberbach; Dianna Milewicz; Carolyn A Bondy
Journal:  Genet Med       Date:  2013-06-06       Impact factor: 8.822

2.  Investigation of Chromosome 1 Aberrations in the Lymphocytes of Prostate Cancer and Benign Prostatic Hyperplasia Patients by Fluorescence in situ Hybridization.

Authors:  Justyna Miszczyk; Mikołaj Przydacz; Michał Zembrzuski; Piotr L Chłosta
Journal:  Cancer Manag Res       Date:  2021-05-31       Impact factor: 3.989

3.  Why it is crucial to analyze non clonal chromosome aberrations or NCCAs?

Authors:  Henry H Q Heng; Sarah M Regan; Guo Liu; Christine J Ye
Journal:  Mol Cytogenet       Date:  2016-02-13       Impact factor: 2.009

Review 4.  The Role of Chromosomal Instability in Cancer and Therapeutic Responses.

Authors:  Natalia Vargas-Rondón; Victoria E Villegas; Milena Rondón-Lagos
Journal:  Cancers (Basel)       Date:  2017-12-28       Impact factor: 6.639

5.  A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients.

Authors:  Andreas Woelfelschneider; Odilia Popanda; Carmen Lilla; Jakob Linseisen; Claudia Mayer; Oktay Celebi; Jürgen Debus; Helmut Bartsch; Jenny Chang-Claude; Peter Schmezer
Journal:  Carcinogenesis       Date:  2008-03-10       Impact factor: 4.944

6.  Spontaneous and radiation-induced chromosomal instability and persistence of chromosome aberrations after radiotherapy in lymphocytes from prostate cancer patients.

Authors:  Andrea Hille; Hana Hofman-Hüther; Elna Kühnle; Barbara Wilken; Margret Rave-Fränk; Heinz Schmidberger; Patricia Virsik
Journal:  Radiat Environ Biophys       Date:  2009-09-18       Impact factor: 1.925

Review 7.  Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems.

Authors:  Christine J Ye; Sarah Regan; Guo Liu; Sarah Alemara; Henry H Heng
Journal:  Mol Cytogenet       Date:  2018-05-10       Impact factor: 2.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.